CG Oncology (CGON) Operating Leases (2023 - 2026)

CG Oncology has reported Operating Leases for 4 years, with the latest figure at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 349.3% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (up 349.3% YoY), and the FY2025 full-year result was $3.1 million, up 5873.08% from the prior year.
• Operating Leases for Q1 2026 stood at $3.5 million, up from $3.1 million in the prior quarter.
• The five-year high for Operating Leases was $3.5 million in Q1 2026, with the low at $52000.0 in Q4 2024.
• Historically, Operating Leases has averaged $1.2 million across 4 years, with a median of $475000.0 in 2023.
• Annual changes were most pronounced in 2024 — Operating Leases slumped 78.69% — and 2025, when it soared 5873.08%.
• CG Oncology's Operating Leases stood at $244000.0 in 2023, then tumbled by 78.69% to $52000.0 in 2024, then soared by 5873.08% to $3.1 million in 2025, then grew by 12.97% to $3.5 million in 2026.
• The last three Operating Leases figures came in at $3.5 million (Q1 2026), $3.1 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.